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Objectives. The parpose of this study was to determine the 
safety and eikaey of thee dosiag regimens of intracoronary 
aroklnose for facilitated aagioplasty of cbroair total native coro- 
nary artery oedasions. 
llac&md Percutaneoes translnminal coronary angioplasty 
of elaanidiy ocdaded (>3 moatbs) native coronary arteries is 
ass&&d with low initial sweess secondmy to an inability to 
pass the guide wire beyond the osdaslon. 
htWods. Patients we emoiled if a duwdc total o&sion >3 
namths old mnki not be crossed with stundnrd angioplasty 
equipment. Of the 101 patients enrow 41 bad saccessfnl pide 
wire passage and were exdaded hrn omkinase treatment. Tbe 
remabdng 60 patients were randomized to receive oae of three 
intromnmay dosing tqimens of q rokinase over 8 b (group A = 
~~U;lgoopB=l~miflmoU;~pC=32milliwU), 
and angioplosty was ag0b1 attempted after completion of the 
nmbhmse~ins8patleItts. 
lledfs. Connauy angioplasty was saceeshl in 32 patients 
(53%) (group A 52%, group B SO%, group C 5970, p = 0.86). Tbis 
study had a 90% power to detect at least a 50% difference between 
dosing groups at alpha 0.05. Bleeding complications reqniring 
bloud transfusion did not differ sign&a&y amang the dosing 
gruups (A O%, B lS%, C 6%, p = 0.14), although major bleeding 
episodes were less common in groap A (p c 0.05). There were no 
q qjor fnwedaral or in-hospital complications. Angi~pbic 
follow-up in 69% of tbe patients with soecessfui angioplasty 
revealed target vessel patency in 91% bat an angiograpbic resten- 
osis rate of 59%. 
CapclkdaRF. A prolonged suprawktive intracoromq iofasion 
of urokinase can be safely administered and may facifiite angio- 
plasty of chronic total occlusions. Lower doses of aroldnase are 
equally etktive and result in fewer bleeding mmplications than 
do bigber dosage re@nens. Vessel patency is keqaently main- 
tain* bat restenosis remains a problem. 
(JAm cd Izhdiol199@27:1406-12) 
Conventional percutaneoas translaminal coronary angioplasty 
of chronically occluded native coronary arteries has been 
associated with lower initial success rates as well as higher 
restenosis rates than those associated with elective angioplasty 
of nonoccluded vessels (I). Reported initial success of angio- 
plasty of chronic total occlusion rates range from 47% to 67% 
(mean t SD 61 2 7%) (l-7). However, the study patients 
were highly selected and many of these series included patients 
with s&acute (<I month) or functional (99% stenosis) occlu- 
sioas, which are associated with better primary success rates. 
Even after successful balloon angioplasty, t&month angio- 
graphic restenosis rates range from 41% to 71% (mean 54 i: 
11%) and reocclusion rates range from 20% to 40% (5-9). 
The most frequent cause for failure of angioplasty in 
:hronic total occlusions is the inability to cross the occlusion 
with a guide wire, particularly in occlusions of >3 months’ 
duration (1411). Reported success rates in this subgroup are 
consistently lower than those associated with more recent total 
occlusions and have ranged between 0% to 55% (12,13). 
Because of the low probability of success, chronic total occla- 
sions of >3 months’ duration are usually not considered for 
percutaneous intervention, and are often referred for bypass 
surgery. However, successful recanalization of chronic total 
occlusions has been shown to reduce angina1 symptoms, de- 
cww the need for coronary artery bypass surgery and im- 
prove left ventricular function (5,14). Thus, new techniques to 
tecanalize chronic total occlusions are of great interest to 
intetventional cardiioaists. 
From the lkpamwni of cardidogy, Department of Medidne. Wtiiam 
-tH~tal~al~MiiThbstudywasfnndedtyan 
Prolonged infusion~f thrombolytic agents has resulted in 
-~grantfmmAbboaLabaatoriR,AbbonParit,IUinds recanalimtion of chronically occluded saphenous vein grafts 
NIanasaiptreeeivedOaober~I995;~maolanipi~~dm- 
ba28.19!%.acoepted~r22.1995. 
and peripheral arteries (l&16). A pilot study of intracoronary 
:Dt.CkdyLGriiw,DireuorofCardii arokinase infusion in native coronary occlusions demonstrated 
Bealasoot Haspit& 3601 west 13 Mile that a prolonged (& to 24-h) infusion coukl be safely per- 
Iomed and appeated to facilitate passage of the guide wire 
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(17). The present larger prospective, randomi-:ed trial was 
performed to determine the safety and efficacy of three dosing 
regimens of intracoronary uroliinase for chronic total native 
corona9 artery occlusions when guide wire passage beyond the 
lesion could not be achieved. 
Methods 
Stu~$ patients. The study group was composed of 101 
patients undergoing elective corona9 augioplasty of a chronic 
occlusion in a native corona9 artery. These patients had 
Canadian Cardiovascuhu Society class II to IV angina or a re- 
versible myocardial perfusion defect in the distribution of a 
corona9 occlusion, or both. Inchtsion criteria included a 
chronic occlusion of >3 months’ duration as assessed by 
previous cardiac catheterization, change in angina1 symptoms 
or a prior failed angioplasty attempt. To ensure adequate 
delivery of urokinase to the point of occlusion, patients with a 
large side branch or with extensive bridging collateral vessels at 
the point of occlusion were excluded. Additional exclusion 
criteria included contraindication to thrombolytii therapy (his- 
to9 of cerebrovascular accident, known bleeding disorder, 
severe uncontrolled hypertension, major surge9 or trauma 
within 60 days), chronic atrial fibrillation with underlying 
mitral valve disorder, and inability to advance the infusion 
catheter to the proximal portion of the occlusion. The study 
protocol was approved by the Institutional Review Board of 
William Beaumont Hospital and written informed consent was 
obtained from each patient before recruitment. 
Urokinase protoml Patients were pretreated with 325 mg 
of chewable aspirin and received a bohrs of 10,000 U of 
intravenous heparin, with additional bohrses given to maintain 
an activated clotting time >300 s. Patients scheduled for a 
urokinase infusiin wem brought to the catheterization lahora- 
to9 in the morning and an attempt was made to cross the 
occlusion with a guide wire. A 7P guiding catheter was inserted 
through the femoral artery and seated in the ostium of the 
occluded corona9 artery. A Touhy-Rorst adapter (ACS) was 
attached to the end of the guiding catheter and a 0.0~in. 
(0.O96-cm) Cragg infusion wire (Meditech) was advanced over 
a O.Ol&in. (0.04ka) guide wire. Guide wires of increasing 
stitbress (Intermediate and Standard wires) were employed 
and an 0.018-m. standard wire was attempted before instituting 
the urokinase infusion in all cases. The 41 patients whose 
lesions were successfully crossed were excluded, whereas the 
remaining 60 patients whose occlusion could not be crossed 
were randomized to one of three urokinase. dosing regimens. 
Contrast medium was injected through the Cragg wire to 
ensure that it was embedded in or just proximal to the 
occlusion. Intracorotuuy urok&se (Abbofrinase, Abbott Iab- 
oratories) was then infused for approximately 8 h through the 
guidingcatbeterpmxim&yandtheCragginfurkwiredii 
taUy. With the use of sealed randomixation errvelqKs Patients 
~rn~~~~~~~~~ 
regimensofm0kinme.Ur0l&sed0aeswerederivedfrom 
prevbusstudieausingurokiMseinfusioosinocdudedsaphe- 
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nous vein grafts. The duration of infusion was limited to 8 h to 
reduce the bleeding complications of a 24-h intusion and to 
maintain catheterization laboratory convenience. Group A 
received SO,OUO U/It of urokinase through the guide catheter 
and 50,000 U/h through the Cragg infusiin wire for a total of 
SOO,ooO U over 8 h. Group B received 100,000 U/h through 
each port for a total of 1.6 mdlion U over 8 h. Group C 
received 200,GfKl U/h through both the guide and the infusion 
wire for a total of 3.2 million U over 8 h. The catheter and the 
femoral sheath were sutured to the skin to ensure stabiity and 
were covered wtth a s&l; dressing 
Patients were then monitored in the cardiac care unit while 
intravenous heparin and intracorona9 urkinase infusions were 
continued. A broad spectmm intravenous antibiotic agent was 
administered during the urokinase infusion. The patient’s 
hemoglobin, fibrinogen, fibrin split products, creatinme kinase, 
activated clotting time and partial thromboplastin time were 
monitored. Activated clotting time was maintained between 
u10 and 250 s while the patient was in the cardiac care unit. 
After -8 h, the patient returned to the catheterization labo- 
ratory for a second attempt to cross the occlusion. A similar 
approach, using wires of increasing stilfness, was again em- 
ployed. If the le+on was sUCCeSSfUlhl cmssed, balloon angio 
plasty was performed. No other interventional devices were 
used during the primary procedure. Procedural success was 
defined as successful guide wire passage and a final residual 
diameter stenosis <50% with Thrombolysis in Myocardial 
Infarction (TIMI) grade 3 llow. Clinical success was defined 
as procedural success without a major in-hospital cardiac 
event. 
FoIIow+p. If the procedure was sllecesw admiistratiotl 
of warfarin was initiated and continued for 3 to 4 months 
(prothrombin time was maintained between 18 and 22 s, 
international normal&d ratio 20 to 3.0), treatment with 
aspirin was mtinued and additionaI medic4 therapy was 
adminktered at the discretion of the cardii Patients with 
sucuMulcoronaryangi0plastyaftertheur0kinaseimWon 
were followed up cbically and were quested to undergo an 
elective stress thalhum test at 3 months and a folhnv-up 
catheterizition at 6 months. Clinkal resteriosis was defined as 
death or the need for target vessel rev- during the 
S-month follow-up period divided by the total number of 
successful angioplasties. Angiogqhk restenosis was delined 
as>5O%diameterstenosisbyquantitatbeangmgmphyinthe 
target Iesion at follow-up. 
bQ%tWcaI aMI+. Immedkte procedural resuk’and 
complications were compared among the umkinase dosing 
groups AU data are dkphyed as a mean value 2 SD. 
Signiseanoetestingwasperformedbyusinganafysisofvari- 
axe (ANOVA) testing where appropriate. Statistii signif- 
cam was accepted at the p < 0.05 level. 
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protocol. Although 101 patients gave consent to enter the 
study, 41 patients did not recei\, urokinase and were excluded 
secondary to successful crossing of the occlusion with the Fide 
wire on the initial attempt (n = 37), contraindications to 
thrombolytic therapy (n = 2) or inability to track the infusion 
catheter into the occlusion (n = 2). Si patients had unsuc- 
cessful angioplasty and were then randomized to receive 
umkinase infusions. Two patients, both randomized to group 
C, required early discontinuation of the urokinase infusion. 
One patient experienced a transient ischemic attack during 
placement of the infusion catheter, although this was not 
recognized until the urokinase infusion was initiated. The 
other patient experienced gastrointestinal bleeding after 
30 min of urokinase infusion, attributed to a Mallory-Weiss 
tear secondary to vomiting that began after the left ventricu- 
@ram was performed. Baseline patient demographics for the 
60 patients randomized are shown in Table 1. 
The mean age of the patients was 56 2 10 years and the 
mean duration of occlusion was 23 + 16 months. The chronic 
occlusion was located in the left anterior descending coronary 
artery in 27%, the leti circumflex coronary artery in 13% and 
the right coronary artery in 60%. The majority of patients had 
Table I. Baseline Characteristics of the 60 Randomized Patient? 
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Figure 1. Flow diagram demonstrating the number 
of patients at each stage of the protocol. Cath = 
cardiac catheterization: PICA = percutaneous 
transluminal coronary angioplasty. 
multiple cardiac risk factors and 33% had prior revasculariza- 
tion. Fifty-two percent of patients had a prior documented 
myocardial infarction in the distribution of the occluded target 
vessel. Eighty-seven percent had at least class II angina1 
symptoms at the time of the procedure, whereas 13% had 
angina-equivalent symptoms (shortness of breath, fatigue) and 
positive findings on a functional test. 
Pmcedural results. All patients had TlMI grade 0 flow at 
the start of the procedure. Fifty-eight patients (97%) com- 
pleted the urokinase infusion and returned for repeat angiog- 
raphy and attempted coronary angioplasty. The urokinase 
infusion improved flow from TIM1 grade 0 to TIM1 grade 1 in 
only 5 patients (9%). Despite the lack of angiographic im- 
provement with urokinase, the guide wire was successfull! 
passed in 34 cases (59%); however, two patients were not 
considered to have had successful angioplasty because of a 
residJ 50% to 70% stenosis and TIMI grade 2 flow. There- 
fore, angioplasty was successful in 32 patients (53%) after the 
urokinase infusion (Fig. 2). Balloon angioplasty success rates 
for groups A, B and C were 52%, 50% and 59%, respectively 
(p = 0.86, chi-square = 0.31, df = 2) (Table 2). A power 
analysis assuming alpha = 0.05 revealed that the study had a 
90% power to detect a ~50% difference between the groups. 
Differences between angioplasty success rates for the three 
major coronary vessels were also not statistically significant 
(p = 0.9J. 
Complications. There were no major procedural complica- 
tions including stroke, need for emergency bypass surgery or 
death, yielding a clinical success rate of 53%. Chest pain 
occurred in 20% of patients during the urokinase infusion; 
however. only one of these patients had ischemic electrocar- 
diographic changes. Two patients (3%) had an embolic event 
manifested by transient visual disturbances-one patient be- 
fore and one after the urokinase infusion was initiated. Non- 
flow-limiting disseaions in 30% of patients were the o&y 
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Figure 2. Selective angiograms of the right 
coronary artery demonstrating total occlusion 
of the distal artery (armw, left pauel). After 
urokinasc was infused for 8 h, angioplasty was 
successful, with a 10% residual s:enosis @raw, 
center paael). Six-month follow-up an&ram 
(right panel) demonstrates a patent vessel with- 
out restenosis. 
angiographic complications. All patients who had unsuccessful 
angioplasty attempts had an uncompliczted hospital course 
without major complications. 
There were no cases of abrupt vessel closure or recurrent 
in-hospital ischemia necessitating repeat intervention. Three 
patients (5%) exhibited elevated levels of creatine kinase, ME 
fraction after the procedure, b-&i a level diagnostic of myocar 
dial infarction (elevation >3 times normal) occurred in only 
one patient (1.6%). Four patients (7%) had bleeding compli- 
cations requiring a blood transfusion; all of these complica- 
tions were attributed to blood loss at the vascular access site. 
Transfusion requirements did not differ significantly among 
the groups (A O%, B 15%, C 6%, p = 0.14). Gastrointestinal 
bleeding not requiring blood transfusion occurred in three 
patients (5%); two of the three had heme-positive stools and 
one patient had a Mallory-Weiss tear. Hematuria also oc- 
curred in two patients (3%). Combined bleeding complications 
including groin bleeding requiring blood transfusion, gastroin- 
testinal bleeding and hematuria were more common in group 
B (25%) and group C (24%) than in the lowest dosing group A 
(4%) (p < 0.05 for group B or C vs. group A). Minor groin 
bleeding (hematomas) not requiring blood transfusion oc- 
curred more frequently in the higher dose groups (A 3570, B 
43%, C 60%, p = 0.2) hut differences were not statistically 
different. 
Follow-up. Twenty-nine of the 32 patients with successful 
coronary ‘angioplasty after the urokinase infusion underwent 
Table 2. Angioplasty Success After Urokinase Infusion 
Urokinase lnh~sion Group 
VeSSel A B C Txal 
LAD 316 35 24 8’15 
LCX 03 33’6 1,: 
RCA 9,17 4!8 7111 ;;j 
Total 1x3 IfEll 1u;17 31’60 
Angioplasty suazss (5) jy+ .5wi 5Yri. 5X 
- 
LAD = k-0 anteriot descending conmq mtety; LCx = kft circumtler 
anonmy artery; RCA = right coron;uy artery. See Methods for detiriiticms of 
gtWpA,BaodC. 
functional stress testing at 3 months. Of these patients, 18 had 
no evidence of &hernia in the distribution of the target vessel, 
4 had fixed defects and 7 had reversibte perfusion abnormali- 
ties. Six-month angiograms were performed in 22 (69%) of the 
32 patients. The remaining 10 patients refused angiographic 
follow-up but were asymptomatic and had negative resuits on 
functional tests. Target vessel patency. defined as L stenosis 
~100% and TIM1 grade 3 flow, was maintained in 20 (91%) of 
the 22 patients with follow-up angiography. However, angio- 
graphic restenosis, defined as a residual diameter stenosis 
>.50%, was seen in 13 (59%) of the 22. 
Clinical 6-month follow-up cn the 32 patients with proce- 
dural success was achieved in 97%. Symptom improvement 
was evaluated zt 6 months by a practitioner who had no 
knowledge of coronary angioplasty results. A decrease in 
angina class or improved exercise tolerance was noted in 28 
(63%) of the 32 patients with angioplasty success. There were 
no recurrent myocardial infarctions, strokes or deaths in the 
&month follow-up period. Clinical restenosis defined as the 
need for target vessel revasctdarizatioc occurred in 13 patients 
(41%); elective bypass surgery was performed in 2 (6%) of 
these patients and repeat target vessel angioplasty in 11(34%). 
The 6-month survival rate was 100%: of patients who under- 
went angiographic follow-up, 91% were ahi with a patent 
target vessel and 68% were alive without the need for a repeat 
revascularixation procedure. Of the 28 patients who had 
umuccessfid angiophtsty after the urokinase infusions only 4 
(14%) noted a decrease in angina class or improved exercise 
tolerance. F&nv-up data for ail 60 patients who underwent 
attempted angioplasty after administration of urokinase dem- 
onstrated repeat percutaneous interventions in 11 (18%) 
bypass surgery in 9 (15%) and death in 0%. The majority 
(seven of nine) of the bypass operations were performed in 
patients who had unsuccessful angioplasty. 
Discussion 
A prolonged infusion of uro!Gmse has proved effective in 
the recanalitation of chronic total ozdusions in peripheral 
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arteries and saphenous vein bypass grafts (15,16). A pilot study 
(17) ezamhting this approach for native coronary arteries 
demonstrated both safety and efficacy; however, the 24-h 
infusion utilized was costly and uncomfortable for the patient. 
Previous reports (18,19) have also documented the success of 
thrombolytic infusions for coronary angioplasty of chronic 
total occhnions. We were able to demonstrate that an 8-h 
infusion of intracoronary urokie?se can frequently facilitate 
balloon angioplasty of chronic total occlusions >3 months 
old. 
RationaIe for recadhation of chronic total occlusions. 
Chronic total occhtsions are the most frequent reason for 
angioplasty faihue and referral for elective bypass surgery (5). 
Although many patients have had myocardial damage in the 
distriiution of the occluded artery, collateral channels often 
maintain myocardial viability (20-22). If the total occlusion 
occurs in a highly diseased segment of the blood vessel without 
prior myocardial infarction, the collateral vessels also maintain 
viability, but the patient presents with a change in angina 
pattern (23). These collateral vessels usually supply sufficient 
blood flow to the affected area during times of physical 
inactivity but frequently become insutlicient when ozygen 
demand is increased (20). Many patients therefore develop 
life style-limiting angina that is often refractory to mazi- 
mlzed medications. Accordingly, attempts to treat chronic 
total occlusion with angioplasty are common and corrprise 
10% to 20% of all angioplasty procedures performed (24). 
The rationale for recanalization of chronic total occlusions 
includes the lessening of clinical symptoms (13), a decreased 
need for bypass surgery (9,13), possible improvement in left 
ventricular function (14,25) and improved survival (6). 
Decreased long-term survival is reported in patients with a 
chronic total occlusion of a single vessel treated medically 
(3,26), and a total occlusion has been associated with a 
higher incidence of sudden death than that of a high grade 
stenosis (27). 
m The composition of the chronic total occlu- 
sion has been shown to include a fibrocalcitic atherosclerotic 
plaque and various degrees of organized thrombus (28). In 
amtmst, fresh occhtsions during myocardial infarction are 
composed of a ruptured fibrous cap overlying soft atheroma 
and a fresh, soft occlusive thrombus (29). In the chronic 
ocdusion, layers of thrombi of different ages may be present, 
each of which is associated with fibrointimal proliferation (28). 
The age and the degree of fibrosis associated with the most 
recent thmmbus is the single most important factor determin- 
ing the likelihood of successful balloon recanalization 
(l,2,6,14,23,30,31). Attempts to pass a guide wire through 
t&e Iesians often lead to mcanahmtion of false lumens and 
~~t~e~inthearterialwall.Wehadhopedto 
tt& advantage of utokinase’s known abiity to activate ilbrin- 
associiltwi with thrmbus, to lyse the 
toftheocdusionaudrestoreanterograde 
~~~~~~.~~~~d~~~e 
afteradministrationofur~ 
~~~~~ 
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to soften the lesion, allowing passage of the guide wire. This 
effect is presumably due to partial lysis of the “freshest” 
thrombus occlcding the lumen. 
Success. Urokinase was able to facilitate angioplasty of 
chronic total occlusions in 55% of cases othenvisc categorized 
as angioplasty failures. The urokinase infusion increased the 
angiopllmty success rate for the 101 patients recruited from 
41% to 72%, a rate that compares favorably with that of 
previous reports (1,2,11-13.32) on angioplasty of &tonic total 
occlusions >3 months old. Because of the enrollnent 
requirement of failed wire passage on initial attemg:; L 
arteries underwent significant manipulation before uroki- 
nase administration. This factor probably led to an in- 
creased rate of vessel disruption and a higher dissection rate 
after angioplasty success was finally achieved. It is possible . 
that starting the urokinase infusion before wiring attempts 
may increase acute procedural success and decrease long- 
term complications. 
Follow-up success. The return of symptoms with a hemo- 
dynamically significant restenosis when the original occlusion 
was total is not unusual. This is secondary to derecruitment of 
collateral vessels after the initial successful angioplasty proce- 
dure (32). In contrast to results in previous studies (8,9) on 
chronic total occlusions, vessel patency was maintained in a 
high percentage (91%) of cases. All patients who did not 
undergo angiographic follow-up were asymptomatic with neg 
at@e results on functional tests. Nevertheless, a high rate of 
angiographic restenosis was observed, which is consistent with 
previous studies (1,5,6,23,30). Given the high incidence of 
restenosis reported for these lesions, stent placement may be 
u&id. Stems have been shown to reduce restenosis rates for 
elective angioplasty of native coronary arteries (33) and would 
probably also decrease long-term complications after angio- 
plasty of chronic total occlusions. 
Recommeudations. Major complications including bleed- 
ing requiring transfusion were uncommon, making this ap- 
proach to chronic total occlusions relatively safe. The two 
neurologic events (transient ischemic attack rate 3%) are of 
some concern; however, only one event occurred aher initia- 
tion of urokinase. Patient immobility during the urokinase 
infusion is critical to minimizing bleeding complications, and 
adequate sedative and pain medications need to be adminis- 
tered to maximize patient comfort Minor bleeding complica- 
tions were more common in the higher dose groups, hut 
success rates did not differ signiticantly among groups. There- 
fore, on the basis of our results, 50,006 U/h per port would be 
the dosage of urokimx recommended for this procedure. 
Because of the increased likelihood of vessel disxction after 
numerous wiring attempts, the urokinase infusion should 
probably be started before vigorous attempts to pass the guide 
wire beyond the occhtsion. If recanalization is achieved, con- 
sider&on should be given to stent placement in an attempt to 
lower reocdusion and restenosis rates . . . Larrutattoasoftkeatudy.ourstudyhasfourptincipal 
Iimitath 1) By flefinitio~ all patients who were emolled had 
Therefore, withii the de- 
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signed protocol, it was not possible to compare urokinase 
infusion with an infusion of placebo. Theoretically, the wiring 
attempts may have been more aggressive after the urokinasc 
infusion or the heparin infusion may have been responsible for 
the increased success rates. This effect would have led to a 
falsely increased need for urokinase and cannot be ruled out 
because of the study design. Although our trial did involve 
randomization to different urokinase dosing regimens, there 
was no placebo infusion group. Because of this limitation, we 
cannot conclusively prove that the success after the infusion 
was solely the result of urokinase administration. However, 
before initiation of urokinase, all patients had failed attempts 
with an O.Ol&in. standard wire which was considered failed 
ang’.oplasty by current standards in our cath laboratory. 
2) Angioplasty equipment has bxome more sophisticated 
since initiation of this sturdy. The more common use of the 
O.Ol&in. glide wire and laser-assisted guide wires may increase 
our ability to cross chronic total occlusions. Both of these new 
technologies, however, also increase the likelihood of finding 
false lumens possibly leading to an increased dissection or 
perforation rate, or both. 
3) The sample size of 60 patients is relatively small, and 
further validation studies with larger patient groups are prob- 
ably warranted. Nevertheless, urokinase was necessary for 
facilitation of angioplasty in 5% of cases, resulted in few 
bleeding complications, and it is currently recommended in 
light of this study’s results, despite the fact that thii study was 
obsetvational without a placebo control group. 
4) Although urokinase was the thrombolytic agent chosen 
for this study, other lytic agents includii strcptokinase or 
recombinant tissue-type plasminogen activator may have led to 
similar success rates. Testing of these other agents in compar- 
ison with urokinase will need to be done in future randomized 
studies. 
Ckmhhm. An g-h supraselective intracoronary infusiin 
of urokinase offers the interventional cardiologist a treatment 
option in the rxanathzation of symptomatic total occlusions 
Sat have been unsuccessfully treated with prior angioplasty 
attempts with standard interventional techniques. Procedural 
success was achieved with lower dose regimens and was 
associated with less bleeding compliitions. Although vessel 
patency was frequently maintained, angiographii restenosis 
remains a problem. Nevertheless, the urokinase infusiin sig- 
nificantly increased the overall rate of angioplasty success in 
chronic total occlusious >3 nonths old and lessened symptoms 
in a large majority rf pari::its. 
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